The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada

International Journal of Clinical Practice

Volumn 68, Issue 5, 2014, Pages 639-646

  Von Wartburg, M ^a   Raymond, V ^b   Paradis, P E ^a,c  

^a GROUPE D ANALYSE   (Canada)

^b PFIZER INC   (United States)

^c AppEco Analytics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; VARENICLINE; NICOTINE GUM;

ADULT; AGED; ARTICLE; CANADA; CLINICAL EVALUATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SMOKING; SMOKING CESSATION; YOUNG ADULT; ADOLESCENT; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE COST; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CANADA; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME; VARENICLINE; YOUNG ADULT;

EID: 84899424999     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12363     Document Type: Article

References (52)

1. Makomaski Illing EM, Kaiserman MJ,. Mortality attributable to tobacco use in Canada and its regions, 1998. Can J Public Health 2004; 95: 38-44.
2. Novotny TE, Giovino GA,. Tobacco use. In:, Brownson RC, Remington PL, Davis JR, eds. Chronic Disease Epidemiology and Control. Washington DC: American Public Health Association, 1998: 117-48.
3. U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
4. Silagy C, Lancaster T, Stead L, Mant D, Fowler G,. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; 3: CD000146.
5. Hughes JR, Stead LF, Lancaster T,. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 31: CD000031.
6. Wu P, Wilson K, Dimoulas P, Mills EJ,. Effectiveness of smoking cessation therapies: A systematic review and meta-analysis. BMC Public Health 2006; 6: 300.
7. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006; 296: 47-55.
8. Cahill K, Stead LF, Lancaster T,. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007; 6103: CD006103.
9. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006; 296: 56-63.
10. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63: 717-24.
11. Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM,. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004; 9: 39-53.
12. Howard P, Knight C, Boler A, Baker C,. Cost-Utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model. Pharmacoeconomics 2008; 26: 497-511.
13. Knight C, Howard P, Baker CL, Marton JP,. The Cost-Effectiveness of an Extended Course (12 + 12 Weeks) of Varenicline Compared with Other Available Smoking Cessation Strategies in the United States: An Extension and Update to the Benesco Model. Value Health 2010; 13: 209-14.
14. Bolin K, Mörk AC, Wilson K,. Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. J Eval Clin Pract 2009; 15: 479-95.
15. CADTH (2010). Pharmacologic-based Strategies for Smoking Cessation: Clinical and Cost-Effectiveness Analyses, CADTH Technology Report, Issue 130. http://www.cadth.ca/media/pdf/H0486-Smoking-Cessation-tr-e.pdf (accessed April 23, 2012).
16. CADTH (2007) CEDAC Final Recommendation Varenicline Tartrate. http://www.cadth.ca/media/cdr/complete/cdr-complete-Champix-August-16-07.pdf (accessed April 23, 2012).
17. Varenicline tartrate (Champix), Final Public Summary Document November 2009 PBAC Meeting, Pharmaceutical Benefits Advisory Committee (PBAC), Australian Government: Department of Health and Aging, November 2009.
18. Varenicline for smoking cessation, NICE Technology Appraisal Guide 123, National Institute for Clinical Health and Excellence (NICE), July 2007.
19. Conseil du Médicament (2010) Capsules CDM Octobre 2010. http://www.inesss.qc.ca/fileadmin/doc/CDM/Inscription-medicaments/Capsules-CDM/ CdM-CapsulesCdM-201010.pdf (accessed April 23, 2012).
20. Provincial/Territorial Governments Implement Effective Smoking Cessation Strategies to Support People in Quit Smoking Efforts. http://www.pfizer.ca/en/ media-centre/news-releases/article?year=2011&article=383 (accessed April 23, 2012).
21. Regie de l'assurance de maladie Quebec (2010) Schedule 1: List of Medications (14 October 2010). https://www.prod.ramq.gouv.qc.ca/DPI/PO/Commun/ PDF/Liste-Med/Liste-Med/liste-med-mod4-2010-10-14-en.pdf (accessed April 23, 2012).
22. Wetter D, Cofta-Gunn L, Fouladi R, Cinciripini P, Sui D, Gritz E,. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 2004; 39: 1156-63.
23. Krall E, Garvey A, Garcia R,. Smoking relapse after 2 years of abstinence: findings from the VA normative aging study. Nicotine Tob Res 2002; 4: 95-100.
24. Canadian Tobacco Use Monitoring Survey (CTUMS) 2005. Ottawa, Ontario: Statistics Canada, 2006.
25. Canadian Community Health Survey (CCHS) Cycle 3.1 2005. Ottawa, Ontario: Statistics Canada, 2006.
26. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics, 2005 Toronto, Ontario: Canadian Cancer Society/National Cancer Institute of Canada, 2005.
27. Ellison LF, Wilkins K,. Cancer prevalence in the Canadian population, Health Report, 20(1), March 2005; Statistics Canada, Catalogue no. 82-003-XPE.
28. Hospital Morbidity Database (HMDB) 2000-2001. Ottawa, Ontario: Canadian Institute for Health Information, 2001.
29. Thun MJ, Apicella LF, Henley SJ,. Smoking vs. other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 2000; 284: 706-12.
30. Cassino C, Ito K, Bader I, Ciotoli C, Thurston G, Reibman J,. Cigarette smoking and ozone-associated emergency department use for asthma by adults in New York City. Am J Respir Crit Care Med 1999; 159: 1773-9.
31. Fiscella K, Franks P,. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians smoking cessation counseling. JAMA 1996; 275: 1247-51.
32. Chapman KR, Bourbeau J, Rance L,. The burden of COPD in Canada: results from the confronting COPD survey. Respir Med 2003; 97 (Suppl. C): S23-31.
33. Ontario Case Costing Initiative (OCCI) 2003/2004. Costs reported by Ontario Case Costing Project (OCCP). Data on file, Pfizer Canada, Inc.
34. Evans WK, Will BP, Berthelot JM, Wolfson MC,. The economics of lung cancer management in Canada. Lung Cancer 1996; 14: 19-29.
35. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: 85-151.
36. Radensky PW, Berliner E, Archer JW, Dournauz SF,. Inpatient costs of major cardiovascular events. Am J Cardiovasc Drugs 2001; 1: 205-17.
37. O'Brien J, Patrick A, Caro J,. Costs of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003; 3: 7.
38. Seung SJ, Mittman N,. Urgent care costs of uncontrolled asthma in Canada, 2004. Can Respir J 2005; 12: 435-6.
39. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation. JAMA 2006; 296: 64-71.
40. Bolin K, Mörk AC, Willers S, Lindgren B,. Varenicline as compared to bupropion in smoking-cessation therapy-Cost-utility results for Sweden 2003. Respir Med 2008; 102: 699-710.
41. Cigarette Prices in Canada, Smoking and Health Action Foundation, Ottawa. www.nsra-adnf.ca (accessed April 23, 2012).
42. Canadian Tobacco Use Monitoring Survey (CTUMS) 2007. Ottawa, Ontario: Statistics Canada, 2008.
43. Ontario Tobacco Research Unit. The Tobacco Control Environment: Ontario and Beyond. Monitoring and Evaluation Series (Vol. 15, No. 1). Tobacco Taxes: Monitoring Update. Toronto, ON: Ontario Tobacco Research Unit, October 29, 2009.
44. National Health Expenditure Trends 1975 to 2009. Ottawa, Ontario: Canadian Institute for Health Information, 2009.
45. Smoking and the Bottom Line: Updating the Costs of Smoking in the Workplace, The Conference Board of Canada, August 2006.
46. Rehm J, Baliunas D, Brochu S, et al. The Cost of Substance Abuse in Canada 2002. Ottawa, Ontario: Canadian Centre on Substance Abuse (CCSA), 2006.
47. Doll R, Peto R, Boreham J, Sutherland I,. Mortality in relation to smoking: 50 years observations on male British doctors. BMJ 2004; 328: 1519-27.
48. Guidelines for the Economic Evaluation of Health Technologies. Canada, Canadian Agency for Drugs and Technologies in Health (CADTH), 3rd Edition 2006.
49. Dagenais GR, Cantin B, Dagenais F, Lupien PJ, Robitaille NM, Bogaty P,. Importance of outside hospital mortality as a first acute ischemic heart event: The Quebec Cardiovascular Study. Can J Cardiol 1996; 12: 914-8.
50. ARIC Community Surveillance, 1987-2000. http://www.cscc.unc.edu/aric/ (accessed April 23, 2012).
51. Kissela B, Scheider A, Kleindorfer D, et al. Stroke in a biracial population: the excess burden of stroke among blacks. Stroke 2004; 35: 426-31.
52. Consumer Price Index (CPI), 2005 Basket, Annual (2002 = 100), CANSIM Table 326-0021. Ottawa, Ontario: Statistics Canada, 2010.